Skip to content

Autologous 3D-DCob First in Human Study for Alveolar Bone Loss

A First-in-Human Study of Autologous 3D-DCob Cell Therapy in Patients with Alveolar Bone Atrophy - A FIH study of Autologus 3D-DCob Cell Therapy in Patients with Alveolar Bone Atrophy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTb060260029
Enrollment
5
Registered
2026-06-09
Start date
2026-06-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar bone atrophy Alveolar bone, Denture, Dental Implant

Interventions

Harvesting of gingival tissue and administration of a specified cell-processed product to the alveolar bone

Sponsors

Kajiya Mikihito
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subjects with the loss of one tooth or two or more consecutive teeth who desire prosthetic treatment using dental implants. 2) Patients diagnosed with alveolar ridge atrophy requiring a bone augmentation procedure due to insufficient bone volume for dental implant placement. 3) Subjects who, as pretreatment, have undergone scaling of the remaining adjacent teeth and received toothbrushing instruction, and whose Plaque Control Record (PCR) is 20% or less.

Exclusion criteria

Exclusion criteria: 1) Patients with a current malignant tumor or a history of malignant tumor within the past 5 years. 2) Patients with a history of drug-induced gingival overgrowth. 3) Patients with poorly controlled respiratory disease or cardiovascular disease. 4) Patients with a smoking history of one or more cigarettes within 1 year prior to obtaining informed consent. 5) Patients with osteoporosis (YAM value <70%, or <80% in those with a history of fragility fracture). 6) Patients with a history of use of medications associated with a risk of medication-related osteonecrosis of the jaw (MRONJ). 7) Patients who test positive on viral screening tests. 8) Patients who are scheduled to undergo surgical treatment at a site adjacent to the investigational site within 48 weeks after transplantation. 9) Patients who participated in another clinical trial/study within 4 weeks prior to enrollment and received administration of an investigational drug, or who are scheduled to participate in another clinical trial during the study period. 10) Patients with metallic restorations in teeth adjacent to the investigational site that may cause artifacts on CBCT images.

Design outcomes

Primary

MeasureTime frame
Safety: Defined as the incidence of adverse events occurring within 3 weeks after transplantation following gingival tissue harvesting.

Secondary

MeasureTime frame
Efficacy: 1) Assessed by the rate of alveolar bone formation on CBCT imaging at 24 weeks after transplantation. 2) Histological analysis of bone tissue at 25 weeks after transplantation.

Countries

Japan

Contacts

Public ContactKajiya Mikihito

Hiroshima University

mkajiya@hiroshima-u.ac.jp+81-82-257-5727

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026